Healthcare in 2022: what you need to know
With the Covid-19 pandemic sending shockwaves in the hospital sector, healthcare providers will continue looking for ways to slowly rebuild …
Post
-
-
Cognita secures FDA breakthrough device designation for CXR
Cognita has received the US Food and Drug Administration (FDA) breakthrough device designation for the Chest X-Ray (CXR) model across …
-
Seqster unveils 1-Click DataLake for clinical trials
Seqster has launched 1-Click DataLake, a real-world data platform to expedite trial design, recruitment, and evidence generation for healthcare and …
-
Liberate Bio gains licences for myeloid-specific CAR design patents
Liberate Bio has obtained both exclusive and non-exclusive licences for patents related to chimeric antigen receptor (CAR) designs tailored for …
-
Philips launches Rembra CT system for acute imaging
Philips has unveiled its next-generation radiology computed tomography (CT) system, Rembra, to address the challenges faced by acute and high-demand …
-
HUTCHMED begins Phase I/IIa trial of HMPL-A580 for solid tumours
HUTCHMED has commenced a Phase I/IIa clinical trial of its second antibody-targeted therapy conjugate (ATTC), HMPL-A580, targeting patients with unresectable, …
-
Healthcare in 2022: what you need to know
With the Covid-19 pandemic sending shockwaves in the hospital sector, healthcare providers will continue looking for ways to slowly rebuild …
-
Affinia receives FDA fast track designation for AFTX-201
Affinia Therapeutics has received the US Food and Drug Administration (FDA) fast track designation (FTD) for AFTX-201, a genetic medicine …
-
Droplet improves genomic analysis speed using NVIDIA Parabricks software
Droplet Biosciences has reported a reduction in genomic analysis turnaround time for residual cancer detection by adopting graphics processing unit …
-
Kyowa Kirin discontinues ongoing trials of rocatinlimab
Kyowa Kirin has announced the global discontinuation of all ongoing clinical trials for rocatinlimab, an anti-OX40 monoclonal antibody under investigation …
-
Esperion to acquire Corstasis for cardiovascular franchise expansion
Esperion Therapeutics has signed a definitive agreement to acquire Corstasis Therapeutics to expand its cardiovascular franchise with the addition of …
-
Roche’s Phase III trial of fenebrutinib in RMS meets primary endpoint
Roche has reported that the pivotal Phase III FENhance 1 trial of its investigational Bruton’s tyrosine kinase (BTK) inhibitor, fenebrutinib, …
-
PHCbi unveils cell expansion system for research use
PHC Corporation’s Biomedical Division (PHCbi) has introduced the cell expansion system, LiCellGrow, designed for research purposes in Japan and certain …
-
Kairos Pharma signs deal for Celyn Therapeutics’ CL-273
Kairos Pharma has signed a binding agreement to acquire exclusive worldwide rights to CL-273 from Celyn Therapeutics, a company backed …
-
FDA grants PMA to Synergy’s cervical disc
Synergy Spine Solutions has received premarket approval (PMA) from the US Food and Drug Administration (FDA) for the Synergy Disc, …
-
Opus Genetics reports Phase I/II trial results of OPGx-BEST1 gene therapy
Opus Genetics has reported early findings from its ongoing Phase I/II clinical trial of the OPGx-BEST1 gene therapy for the …
-
BioMarin receives FDA approval for Palynziq use in adolescents
BioMarin Pharmaceutical has received the US Food and Drug Administration (FDA) approval for its supplemental biologics licence application (sBLA) for …
